Akari Therapeutics, Plc (AKTX) |
|
4.0001 0.15 (3.9%)
|
09-26 15:01 |
|
Open: |
3.7 |
Pre. Close: |
3.85 |
|
High:
|
4.3899 |
Low:
|
3.7 |
|
Volume:
|
52,882 |
Market Cap:
|
20(M) |
|
|
|
Technical analysis |
as of: 2023-09-26 2:47:04 PM |
|
Short-term rate:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 5.12 One year: 5.98 |
| Support: |
Support1: 3.53 Support2: 3 |
| Resistance: |
Resistance1: 4.38 Resistance2: 5.12 |
| Pivot: |
3.64 |
| Moving Average: |
MA(5): 3.73 MA(20): 3.55
MA(100): 3.7 MA(250): 6.53  |
| MACD: |
MACD(12,26): 0 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 77.8 %D(3): 69.9 |
| RSI: |
RSI(14): 59.9 |
| 52-week: |
High: 13.39 Low: 2.79 |
| Average Vol(K): |
3-Month: 32 (K) 10-Days: 13 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AKTX ] has closed Bollinger Bands are 38% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.99 - 4.01 |
4.01 - 4.02 |
|
Low:
|
3.27 - 3.29 |
3.29 - 3.31 |
|
Close:
|
3.81 - 3.85 |
3.85 - 3.88 |
|
Company Description |
|
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom. |
Headline News |
Thu, 21 Sep 2023
Akari Therapeutics Announces Existing Investors Support the ... - BioSpace
Thu, 21 Sep 2023
Akari Therapeutics Secures Financing and RD Tax Credit Advances ... - Best Stocks
Tue, 19 Sep 2023
Akari Therapeutics to Host Key Opinion Leader Webinar on ... - Marketscreener.com
Tue, 19 Sep 2023
Akari Therapeutics to Host Key Opinion Leader Webinar on ... - GlobeNewswire
Thu, 07 Sep 2023
Healthcare Stocks on the Move Thursday: THTX, AAWH, CCHWF, AKTX, NBSE, CRVS, ICCT, NEOG - InvestorsObserver
Tue, 05 Sep 2023
Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid ... - BioSpace
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
5 (M) |
| Shares Float |
3 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
0 (%) |
|
Shares Short
|
8 (K) |
|
Shares Short P.Month
|
12 (K) |
Stock Financials |
|
EPS
|
-5.43 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.47 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-113.3 |
|
Return on Equity (ttm)
|
-483.3 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-4.57 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-22 (M) |
|
Levered Free Cash Flow
|
-6 (M) |
Stock Valuations |
|
PE Ratio
|
-0.76 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
8.53 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.97 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
